Plain-English translation of NCT07483554 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This Phase II clinical trial is testing a new medication called IBI343 combined with standard chemotherapy to treat advanced stomach, gastroesophageal junction, or pancreatic cancers. The study focuses on patients whose cancers have a specific protein marker called CLDN18.2, which may make them more likely to respond to this treatment. Researchers will evaluate whether this medication is safe and how well it works when combined with other cancer therapies.
Advanced stomach and pancreatic cancers are difficult to treat, and many patients need better treatment options. This medication targets a specific protein found on these cancer cells, offering a potentially new approach to help patients with these cancers live longer and have better outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive IBI343 in combination with standard chemotherapy according to a treatment schedule set by the research team. You'll have regular clinic visits for physical exams, blood tests, and imaging scans to monitor how well the treatment is working and check for side effects. The study involves about 389 patients total, and your participation would include careful tracking of your response to treatment and how you tolerate the medication over time.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China